Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer

Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00239551

Enrollment

Registered

2005-10-17

Start date

2005-10-31

Completion date

2007-12-31

Last updated

2013-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach Ulcer

Keywords

gastric stress ulcer, Prevacid, Prostaglandin

Brief summary

The purpose of this study is to measure the prostaglandin levels in patients with stress ulcer and the effect of Prevacid on prostaglandin levels in patients with stress ulcer.

Detailed description

The prostaglandin system plays an important role in the gastric mucosa to strengthen its resistance against injury. Critically ill patients are at greatest risk of developing stress-related gastric mucosal lesions. Although the levels of prostaglandins in gastric mucosa in patients with stressed animal has been studied, prostaglandin levels in the gastric mucosa in patients with stress ulcer have not been studied and the effect of Prevacid on prostaglandin levels in gastric mucosa from patients with stress ulcer is unknown. We hypothesize that prostaglandin levels are low in the gastric mucosa in patients with stress ulcer, and Prevacid is an effective agents in increasing prostaglandin levels in the gastric mucosa in stress stress ulcer. Comparison(s): The prostaglandin levels in patients who treated with Prevacid for stress ulcer, compared to the prostaglandin levels in patients who treated with H2 blocker for stress ulcer.

Interventions

DRUGPrevacid

Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 & EGD with biopsy at 8 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients in ICU with documented gastric stress ulcer by endoscopic examination, including patients with H. Pylori infection; * Patients have no known ulcer within 8 weeks prior to be admitted to ICU; * Patients not on any PPI for 4 weeks prior to the study; * Patients or family be consented for the study.

Exclusion criteria

* Patients have gastric ulcer within 8 weeks prior to be admitted to ICU; * Patients have gastric cancer confirmed by pathology; * Patients on one of the PPIs already; * Patients on any of the Non-steroidal Antiinflammatory Drugs.

Design outcomes

Primary

Measure	Time frame
the effect of Prevacid on prostaglandin levels at 8 weeks	8 weeks

Secondary

Measure	Time frame
esophagogastroduodenal endoscopy(EGD) with biopsy at day 1; EGD with biopsy at 8 weeks	8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026